GlassScriptPhysician profile
Sandra Flores
NPI 1972035905
$3,177.87
in general payments reported to CMS, 2019-2025
13 companies · $2,131 in 2025
The $2,131 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $43.48 · 2022: $108 · 2023: $565 · 2024: $330 · 2025: $2,131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,843 · Travel and Lodging: $1,138 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,843.11 |
| Travel and Lodging | $1,138.20 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aesculap, INC. | $1,388.20 | 2025 | Xabo |
| Medtronic, INC. | $575.14 | 2022-2025 | Aquamantys(Tm), Strata, Stealthstation S8 Platform |
| Ucb, INC. | $288.28 | 2025 | Fintepla, Briviact, Neupro |
| Genzyme Corporation | $253.03 | 2024-2025 | |
| Aerin Medical INC. | $232.39 | 2024-2025 | |
| Medical Device Business Services, INC. | $120.52 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $75.94 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $69.23 | 2024-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $45.37 | 2024 | Farxiga |
| Idorsia Pharmaceuticals US INC | $44.69 | 2023 | Quviviq |
| Stryker Corporation | $43.48 | 2021 | |
| Itamar Medical INC | $26.60 | 2024 | Watchpatone |
| Amgen INC. | $15.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Flores listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.